{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:43:21Z","timestamp":1787024601592,"version":"build-2736575974"},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.2169\/internalmedicine.5475-25","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T18:08:29Z","timestamp":1747850909000},"page":"2332-2337","source":"Crossref","is-referenced-by-count":1,"title":["Loeffler Endocarditis with Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination"],"prefix":"10.2169","volume":"64","author":[{"given":"Hiroaki","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuna","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Umeda","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yoshimuta","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Maemura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hoxha A, Tomaselli T, Minicucci GM, et al. Hypereosinophilic syndrome following the BNT162b2 (BioNTech\/Pfizer) vaccine successfully treated with mepolizumab: a case report and review of the literature. J Clin Med 12: 2376, 2023.","DOI":"10.3390\/jcm12062376"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Benezet-Mazuecos J, de la Fuente A, Marcos-Alberca P, Farre J. Loeffler endocarditis: what have we learned? Am J Hematol 82: 861-862, 2007.","DOI":"10.1002\/ajh.20957"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tiwari A, Karna G, Chakrabarti SS, Panda PK, Kaur U. Hyper-eosinophilic syndrome with myocarditis after inactivated SARSCoV- 2 vaccination - a case study. Curr Drug Saf 18: 103-106, 2023.","DOI":"10.2174\/1574886317666220509165317"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Janga C, Patel T, Hennawi HA, et al. Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine. Glob Cardiol Sci Pract 2023: e202310, 2023.","DOI":"10.21542\/gcsp.2023.10"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ohtani K, Takahama S, Kato S, Higo T. Acute necrotizing eosinophilic myocarditis after COVID-19 vaccination. Eur Heart J 43: 2640, 2022.","DOI":"10.1093\/eurheartj\/ehac239"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Prabhahar A, Naidu GSRSNK, Chauhan P, et al. ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review. Rheumatol Int 42: 749-758, 2022.","DOI":"10.1007\/s00296-021-05069-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shakoor MT, Birkenbach MP, Lynch M. ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis 78: 611-613, 2021.","DOI":"10.1053\/j.ajkd.2021.06.016"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Suzuki M, Sekiguchi Y, Sasaki M, et al. Antineutrophil cytoplasmic antibody-associated vasculitis after COVID-19 vaccination with Pfizer-BioNTech. Intern Med 61: 2925-2929, 2022.","DOI":"10.2169\/internalmedicine.9807-22"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takenaka T, Matsuzaki M, Fujiwara S, Hayashida M, Suyama H, Kawamoto M. Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA coronavirus disease-19 vaccine. QJM 114: 737-738, 2021.","DOI":"10.1093\/qjmed\/hcab227"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yoshino Y, Ishida T. Anti-neutrophil cytoplasmic antibody-associated vasculitis with periaortitis that developed after mRNA COVID-19 vaccination. Cureus 15: e37480, 2023.","DOI":"10.7759\/cureus.37480"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yoshino Y, Yamanaka Y, Oda A. Otitis media with ANCA-associated vasculitis following COVID-19 mRNA vaccination: a case report. Am J Case Rep 25: e945301, 2024.","DOI":"10.12659\/AJCR.945301"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. El Hasbani G, Uthman I. ANCA-associated vasculitis following the first dose of Pfizer-BioNTech COVID-19 vaccine. Nephron 147: 103-107, 2023.","DOI":"10.1159\/000525562"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kim BC, Kim HS, Han KH, Han SY, Jo HA. A case report of MPO-ANCA-associated vasculitis following heterologous mRNA1273 COVID-19 booster vaccination. J Korean Med Sci 37: e204, 2022.","DOI":"10.3346\/jkms.2022.37.e204"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nishioka K, Yamaguchi S, Yasuda I, et al. Development of alveolar hemorrhage after Pfizer-BioNTech COVID-19 mRNA vaccination in a patient with renal-limited anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. Front Med (Lausanne) 9: 874831, 2022.","DOI":"10.3389\/fmed.2022.874831"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Feghali EJ, Zafar M, Abid S, Santoriello D, Mehta S. De-novo antineutrophil cytoplasmic antibody-associated vasculitis following the mRNA-1273 (Moderna) vaccine for COVID-19. Cureus 13: e19616, 2021.","DOI":"10.7759\/cureus.19616"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hakroush S, Tampe B. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizer-BioNTech COVID-19 mRNA vaccination. Front Immunol 12: 762006, 2021.","DOI":"10.3389\/fimmu.2021.762006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chen CC, Chen HY, Lu CC, Lin SH. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage may occur after COVID-19 vaccination. Front Med (Lausanne) 8: 765447, 2021.","DOI":"10.3389\/fmed.2021.765447"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Okuda S, Hirooka Y, Sugiyama M. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis after COVID-19 vaccination. Vaccines (Basel) 9: 842, 2021.","DOI":"10.3390\/vaccines9080842"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Costanzo G, Ledda AG, Ghisu A, Vacca M, Firinu D, Del Giacco S. Eosinophilic granulomatosis with polyangiitis relapse after COVID-19 vaccination: a case report. Vaccines (Basel) 10: 13, 2021.","DOI":"10.3390\/vaccines10010013"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gill R, Rizvi M, Sadiq MS, Feldman M. Recrudescence of severe polyneuropathy after receiving Pfizer-BioNTech COVID-19 vaccine in a patient with a history of eosinophilic granulomatosis with polyangiitis. BMJ Case Rep 15: e245749, 2022.","DOI":"10.1136\/bcr-2021-245749"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hwang YK, Kwak HH, Yun JE, Kim SH, Chang YS. Eosinophilic granulomatosis with polyangiitis following COVID-19 vaccination: a case report. J Korean Med Sci 38: e382, 2023.","DOI":"10.3346\/jkms.2023.38.e382"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ibrahim H, Alkhatib A, Meysami A. Eosinophilic granulomatosis with polyangiitis diagnosed in an elderly female after the second dose of mRNA vaccine against COVID-19. Cureus 14: e21176, 2022.","DOI":"10.7759\/cureus.21176"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Karampoor S, Afrashteh F, Rahmani S, Laali A. Eosinophilic granulomatosis with polyangiitis after COVID-19: a case report. Respir Med Case Rep 38: 101702, 2022.","DOI":"10.1016\/j.rmcr.2022.101702"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lai YW, Chua CG, Lim XR, Francis PJ, Xu C, Howe HS. Autoimmune rheumatic disease flares with myocarditis following COVID-19 mRNA vaccination: a case-based review. Vaccines (Basel) 10: 1772, 2022.","DOI":"10.3390\/vaccines10101772"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mahdi S, Joudeh AI, Raman KS, et al. New-onset severe eosinophilic granulomatosis with polyangiitis following the third dose of mRNA COVID-19 vaccine: a case report. Mod Rheumatol Case Rep 8: 153-158, 2023.","DOI":"10.1093\/mrcr\/rxad043"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mencarelli L, Moi L, Dewarrat N, et al. Eosinophilic granulomatosis with polyangiitis after mRNA-1273 SARS-CoV-2 vaccine. Vaccines (Basel) 11: 1335, 2023.","DOI":"10.3390\/vaccines11081335"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Nappi E, De Santis M, Paoletti G, et al. New onset of eosinophilic granulomatosis with polyangiitis following mRNA-based COVID-19 vaccine. Vaccines (Basel) 10: 716, 2022.","DOI":"10.3390\/vaccines10050716"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Akkuzu G, Bes C, \u00d6zg\u00fcr DS, et al. Inflammatory rheumatic diseases developed after COVID-19 vaccination: presentation of a case series and review of the literature. Eur Rev Med Pharmacol Sci 27: 2143-2151, 2023.","DOI":"10.1111\/1756-185X.14852"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sato T, Umeda M, Sato S, et al. Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era. Clin Immunol 252: 109656, 2023.","DOI":"10.1016\/j.clim.2023.109656"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Yang Y, Xiong Y, Xu G. New insights of antineutrophil cytoplasmic antibody-associated vasculitis from the perspective of COVID-19 vaccination. Clin Exp Immunol 213: 301-309, 2023.","DOI":"10.1093\/cei\/uxad043"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kawamura T, Nakazawa D, Nishio S, Isozaki T, Komatsumoto M, Atsumi T. Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele. Mod Rheumatol Case Rep 7: 426-430, 2023.","DOI":"10.1093\/mrcr\/rxac093"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Karthikeyan K, Balla S, Alpert MA. Non-infectious aortic and mitral valve vegetations in a patient with eosinophilic granulomatosis with polyangiitis. BMJ Case Rep 12: e225947, 2019.","DOI":"10.1136\/bcr-2018-225947"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Aydo\u011fdu S, U\u00e7ar O, Cetin M. A case of systemic lupus erythematosus presenting with hypereosinophilia and Loeffler endocarditis. Acta Cardiol 65: 571-573, 2010.","DOI":"10.1080\/AC.65.5.2056245"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_5475-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:16:50Z","timestamp":1754108210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_5475-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5475-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"5475-25"}}